Terminal and Site-Specific PEGylationAffinity-Preserving ConjugationAptamer-Drug Conjugate Support
Pegylated aptamer services attach polyethylene glycol chains to DNA or RNA aptamers to extend circulation time, slow renal clearance, improve nuclease resistance, and lower immunogenic or non-specific interactions. PEGylation turns a short, rapidly cleared oligonucleotide into a more durable research and therapeutic-style reagent. Done with the binding interface in mind, it adds pharmacokinetic support without erasing the affinity that makes the aptamer useful. We focus on conjugating PEG at positions that preserve the aptamer fold, using terminal, site-specific, or click routes chosen by the sequence and its target, so the molecule gains stability while keeping the property you selected it for.
We focus on conjugating PEG at positions that preserve the aptamer's binding interface, using terminal, site-specific, or click routes chosen by the aptamer sequence and its target. Work connects to aptamer conjugation services, aptamer-drug conjugation (ApDC), oligonucleotide bioconjugation, and broader PEGylation capabilities, so a project that needs both stabilization and targeting can be built as one coordinated effort.
Aptamers are powerful binders but short-lived in vivo: they are cleared by the kidney within minutes and degraded by nucleases, and they can provoke non-specific or immune responses. PEGylation helps, but done blindly it shields the binding site and destroys affinity. Teams also struggle with heterogeneous products where the PEG substitution is unknown, so one batch binds and the next does not. The need is PEG placed where it helps stability without erasing the very property that makes the aptamer useful, and characterized well enough to reproduce.
A sound PEGylation strategy treats molecular weight, branching, attachment site, and spacer length as connected variables that set half-life, shielding, and binding retention. This matters because the same aptamer must often remain target-active while surviving serum, clearance, and delivery. We select PEG size and architecture from the clearance and stability target, then measure binding before and after so the trade-off is explicit rather than assumed.
Schematic of a PEGylated aptamer retaining target binding while gaining stability through PEG shielding.Dense or misplaced PEG hides the aptamer fold. We conjugate at the non-binding terminus or via a spacer so the binding interface stays free, and we verify binding after conjugation.
Linker and site choice directly affect KD. We measure binding before and after PEGylation and adjust site or PEG size so affinity stays within the acceptable range for the assay.
Too little PEG clears fast; too much adds viscosity and cost. We select PEG size, often 20 kDa or larger, for the clearance target while keeping the product workable.
Poorly controlled PEGylation gives heterogeneous products. We report substitution and use purified, low-polydispersity PEG reagents, and we separate unconjugated and over-conjugated species.
We provide PEGylated aptamers from simple terminal PEGylation to site-specific and click routes, and we support aptamer-drug conjugate assembly where PEG improves pharmacokinetics. Each project is scoped from the aptamer sequence, its target and binding site, and the stability or clearance goal.
Terminal PEGylation of AptamersCapabilities include:
Typical applications:
Stable, longer-circulating aptamers for research and conjugate work.
Site-Specific and Click PEGylationCapabilities include:
Typical applications:
PEGylated aptamers where affinity retention is critical.
PEGylated Aptamer-Drug Conjugate (ApDC) AssemblyCapabilities include:
Typical applications:
Targeted, stabilized aptamer therapeutics-style constructs.
Characterization and OptimizationCapabilities include:
Typical applications:
Release-ready PEGylated aptamers with a defined profile.
Aptamer PEGylation is not one reaction but a set of routes, each with a different effect on the binding interface. The comparison below ties the route to the actual construct rather than to a default choice, so the conjugation protects affinity while adding stability.
| PEGylation route | Aptamer handle | PEG architecture | Effect on binding | Best use |
| Terminal (3'/5') PEGylation | Amino or thiol at end | Linear or branched | Low if distal to binding site | General stabilization, ApDC base |
| Site-specific click PEGylation | Azide or DBCO internally | Defined placement | Minimal when spaced | Affinity-critical constructs |
| Branched PEG shielding | Terminal handle | Two-arm branched | Strong shielding, watch site | Maximum clearance reduction |
| Brush / dense PEG | Multiple handles | High-density | Risk to affinity | Specialized stealth needs |
The PEG form and molecular weight decide how much clearance is reduced and how much shielding is added, at the cost of viscosity and, at high density, affinity. This menu summarizes the trade-offs we use when selecting PEG for an aptamer, with values intended as planning guidance.
| PEG form | Molecular weight | Branching | Effect on clearance / shielding | Key trade-off |
| Linear mPEG | 2 to 10 kDa | No | Moderate clearance reduction | Low viscosity, mild shielding |
| Linear high-MW mPEG | 20 to 40 kDa | No | Strong clearance reduction | Viscosity rises with size |
| Branched PEG | 20 to 40 kDa (2-arm) | Yes | Maximum shielding, strong clearance reduction | Larger hydrodynamic size |
| Multi-arm / dense brush | 40 kDa and above | Yes | Strongest stealth effect | Higher risk to affinity; aggregation |
| Cleavable PEG | Variable | Optional | Tunable by condition | Adds synthesis complexity |
Delivered PEGylated aptamer is characterized so you can judge stability and binding, rather than only confirm that PEG is present. The specifications below are reported per project; exact ranges depend on aptamer and PEG choice.
| Specification | Typical range or option | Notes |
| Aptamer type | DNA or RNA aptamer | Sequence provided by client |
| PEG size | 2 kDa to 40 kDa; branched options | Selected for clearance target |
| Conjugation site | Terminal or site-specific | Chosen to preserve binding |
| Degree of PEGylation | Reported per molecule | MS-based quantification |
| Binding affinity | KD by SPR or equivalent | Measured before and after |
| Stability | Serum and nuclease resistance assessed | Reported where relevant |
We review sequence, target, binding site, and whether PEG is for stability, clearance, or conjugate use, so the conjugation strategy fits the molecule and the application.
Terminal, site-specific, or click route is chosen to protect the binding interface, with site or spacer selected from the known fold.
PEG is attached and heterogeneous species are separated to a defined product, removing free PEG, unconjugated aptamer, and over-conjugated material.
Degree of PEGylation, purity, and binding affinity are measured, and the substitution is confirmed rather than assumed.
Serum and nuclease resistance are tested where relevant to the application, so the stabilized aptamer is judged under realistic conditions.
Final material ships with substitution, affinity, and handling guidance, plus the batch record needed to reproduce the result.
We conjugate away from the binding interface or via a spacer, so PEGylation extends half-life without erasing affinity, and we confirm binding retention by measurement.
Terminal, site-specific, and click routes are selected by sequence and target rather than applied uniformly, so the chemistry fits the fold.
Degree of PEGylation is measured by mass spectrometry so the product is characterized, not assumed, and batches can be matched.
PEGylation is integrated with aptamer-drug conjugate assembly where pharmacokinetic support is needed, so stabilization and targeting are built together.
Whether you are stabilizing an aptamer against clearance, building a site-specific PEGylated binder, or assembling a PEGylated aptamer-drug conjugate, we provide technically focused support across conjugation and characterization. We plan the PEG to protect the function you selected the aptamer for.
We work with customer-defined aptamer sequences, PEG sizes, and conjugate goals, and deliver material with the analytical data to evaluate and reproduce it. custom bioconjugation support and contact our scientific team to discuss your pegylated aptamer requirements and request a project-specific proposal.
It is a DNA or RNA aptamer with one or more polyethylene glycol chains attached. PEGylation improves circulation time, nuclease resistance, and reduces rapid renal clearance and non-specific interactions, which makes the aptamer more durable for research and therapeutic-style use.
It can if PEG is placed on or near the binding interface. We conjugate at the non-binding terminus or via a spacer, and we measure affinity before and after to confirm retention within the acceptable range.
Larger PEG, often 20 kDa or more, reduces renal clearance more effectively, while branched PEG adds stronger shielding. We select size and architecture by the clearance and stability target, balancing shielding against viscosity and affinity.
Yes. Using an azide- or DBCO-modified aptamer with click-compatible PEG lets us place PEG at a defined position, minimizing perturbation of the binding fold and giving a more homogeneous product.
We determine the degree of PEGylation by mass spectrometry and assess purity and heterogeneity, so the substituted product is characterized rather than assumed, and batches can be matched.
Delivered material is for research use only. Pegaptanib is a precedent therapeutic aptamer, but our services supply research-grade reagents and are not for clinical or therapeutic application.
